Results 121 to 130 of about 32,890 (266)

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14 [PDF]

, 2018
Pityriasis rubra pilaris (PRP) represents a group of rare chronic inflammatory skin disorders in which ~1 in 20 affected individuals show autosomal dominant inheritance.
Hsu, C-K, Levell, N J, Lwin, S M, McGrath, J A   +3 more
core   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma [PDF]

, 2013
BACKGROUND: To identify demographic and clinical characteristics associated with cases of hepatosplenic T-cell lymphoma (HSTCL) in patients with Crohn’s disease, and to assess strength of evidence for a causal relationship between medications and HSTCL ...
Elizabeth Chairez, Eric B Bass, Lisa M Wilson, Mark Lazarev, Saranya A Selvaraj, Susan Hutfless   +5 more
core   +1 more source

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]

, 2019
Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos, Navarro-Artieda, Ruth, Sicras-Mainar, Antoni   +2 more
core   +2 more sources

REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough, Fiona McEvoy, Moneeb Saddiq, Michael O'Connell, Maeve Lynch, Brian Kirby, Michelle Murphy   +6 more
wiley   +1 more source

Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies

Diseases
Background: Ustekinumab and vedolizumab represent both valid therapeutic options in patients with Crohn’s Disease. Data comparing the safety and efficacy of these drugs are indirect, with conflicting results reported.
Andrea Pasta, Francesco Calabrese, Elisa Marabotto, Manuele Furnari, Maria Giulia Demarzo, Raffaele Pellegrino, Antonietta Gerarda Gravina, Alessandro Federico, Edoardo Giovanni Giannini, Giorgia Bodini   +9 more
doaj   +1 more source

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Cost Effectiveness and Resource Allocation, 2018
Background Human monoclonal antibody ustekinumab is a novel Crohn’s disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study’s objective was to assess cost-effectiveness of ustekinumab in moderate to severely active CD ...
Amanda Hansson-Hedblom, Chrissy Almond, Fredrik Borgström, Indeg Sly, Dana Enkusson, Anders Troelsgaard Buchholt, Linda Karlsson   +6 more
doaj   +1 more source

Treatment-resistant ulcerative necrobiosis lipoidica in a diabetic patient responsive to ustekinumab [PDF]

, 2019
Necrobiosis lipoidica is a chronic granulomatous disease of unknown etiopathogenesis, which is often difficult to treat. While data from randomized controlled trials for the treatment of necrobiosis lipoidica is lacking, several treatments of varying ...
Pourang, Aunna, Sivamani, Raja K
core  

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
The results of a geriatric assessment in older patients with IBD were associated with adverse health outcomes. Frailty, reflected by severe deficits in geriatric assessment, was independently associated with all‐cause and acute hospitalisations in older patients with IBD. ABSTRACT Background Guidelines recommend considering frailty in the management of
Anne B. Fons, Vera E. R. Asscher, Rogier J. L. Stuyt, A. Martine C. Baven‐Pronk, Sander van der Marel, Rutger J. Jacobs, Jeoffrey J. L. Haans, Andrea E. van der Meulen‐de Jong, Simon P. Mooijaart, Kees. J. Kalisvaart, P. W. Jeroen Maljaars   +10 more
wiley   +1 more source